medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

1999, Number 4

<< Back Next >>

An Med Asoc Med Hosp ABC 1999; 44 (4)

Idiopathic inflammatory myopathy: Characteristics in the Mexican population

Andrade-Ortega L, Irazoque-Palazuelos F

Language: Spanish
References: 38
Page: 153-158
PDF size: 190.68 Kb.


ABSTRACT

Most of the clinical descriptions of idiopathic inflammatory myopathies (IIM) belong to the American and European literature. There are very few studies describing Mexican patients. We reviewed the characteristics of 42 patients with IIM followed in the Rheumatology Department of the Centro Médico Nacional 20 de Noviembre of the Instituto de Seguridad y Servicio Social para Trabajadores del Estado in Mexico City from January, 1996 to July, 1997. Thirty-four patients were women and 8 were men. The IIM was classified as primary polymyositis in 12, dermatomyositis in 22, childhood IIM in 6, and IIM associated with another connective tissue disease in 2. Median age at diagnosis was 33.3 years in the adult cases, and 7 years in the pediatric cases. There was a high (84%) prevalence of nonspecific symptoms prior to the onset of weakness and skin lesions. The disease was self-limited in 15 patients, had flares and remissions in 23, and was progressive in 4. Dermatomyositis was more prevalent in our population than in other studies. It also had an earlier age of onset, a more aggressive course, and a worse prognosis compared with the other types of IIM. Only 19% of patients remitted with steroid therapy; the remaining required the addition of one or two immunosuppressive drugs. There was a significant statistical relationship between an early treatment and a better chance of remission.


REFERENCES

  1. Medsger TA, Oddis CV. Inflammatory muscle disease. In: Klippel JH, Dieppe PA (eds). Rheumatology. 2nd ed. London: Mosby, 1998; 7: 13.1-13.4.

  2. Morrow J, Nelson L, Watts R et al. Polymyositis. In: Autoimmune rheumatic disease. 2nd ed. New York, Oxford: University Press, 1999: 170-190.

  3. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Eng J Med 1975; 292: 344-347, 403-407.

  4. Walton JN, Adams Rd (eds). Polymyositis. Baltimore: Williams & Wilkins, 1958.

  5. Banker BQ, Engel AG. The Polymyositis and dermatomyositis syndromes. In: Engel AG, Banker BQ (eds). Myology. Vol 2. New York: MacGraw-Hill, 1986: 1385-1422.

  6. Love LA, Leff RL, Fraser DD et al. A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70: 360-374.

  7. Miller FW. Myositis-specific autoantibodies: Touch-stones for understanding the inflammatory myopathies. JAMA 1993; 270: 1846-1849.

  8. Plotz PH, Rider LG, Targoff IN et al. Myositis: Immunologic contributions to understanding cause, pathogenesis and therapy. Ann Intern Med 1995; 122: 715-724.

  9. Calabrese LH, Chou SM. Inclusion body myositis. Rheum Dis Clin North Am 1994; 955-972.

  10. Medsger TA, Dawson WN, Masi AT. The epidemiology of polymyositis. Am J Med 1970; 48: 715-723.

  11. Oddis CV, Conte CG, Steen VD, Mesger TA Jr. Incidence of PM-DM: A 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol 1990; 17: 1329-1334.

  12. Reichlin M, Arnett FC. Multiplicity of autoantibodies in myositis sera. Arthritis Rheum 1984; 27: 1150-1156.

  13. Medsger TA Jr. Inflammatory diseases of muscle. In: Kelley WN (ed). Textbook of internal medicine. Philadelphia: JB Lippincott; 1989; 1: 1007-1009.

  14. Oddis CV, Medsger TA Jr, Cooperstein LA. A subluxing arthropathy associated with the anti-Jo-1 antibody in polymyositis/dermatomyositis. Arthritis Rheum 1990; 33: 1640-45.

  15. Heffner RR, Barron SA, Jenis EH, Valeski JE. Skeletal muscle in polymyositis. Arch Pathol Lab Med 1979; 103: 310-313.

  16. Uthman I, Vazquez-Abad D, Senecal JL. Distinctive features of idiopathic Inflammatory myopathies in French Canadians. Semin Arthritis Rheum 1996; 26: 447-458.

  17. Salazar-Paramo M, Gonzalez-Covarrubias I, Garcia-De La Torre I. Clinical and serological characteristics in a group of Mexican patients with juvenile dermatomyositis. Rev Bras Reumatol 1998; 38: 5.

  18. Garcia-De La Torre I, Ramirez-Casillas A, Hernandez-Vazquez L. Acute familial myositis with a common autoimmune response. Arthritis Rheum 1991; 34: 744.

  19. Okada S, Rider LG, Prasad K, García De La Torre I et al. Latitudinal gradients in the relative prevalence of dermatomyositis and its associated autoantibody, anti-Mi-2 in idiopathic inflammatory myopathy. Arthritis Rheum (abst.) 1996; 39: S191 (984).

  20. Moyer RA, Phillips CA, Torretti D et al. Clinical features and outcome in inflammatory myopathy. Arthritis Rheum 1989; 32: A120-S32.

  21. Joffe MM, Love LA, Leff RL et al. Drug therapy of the idiopathic inflammatory myopathies: Predictors of response to prednisone, azathioprine and methotrexate and a comparison of their efficacy. Am J Med 1993; 94: 379-387.

  22. Schulman P, Kerr LD. A reexamination of the relationship between myositis and malignancy. J Rheumatol 1991; 18: 1689-1692.

  23. Callen JP, Hyla JF, Bole GG Jr, Kay DR. The relationship of dermatomyositis/polymyositis to malignancy. J Rheumatol 1991; 18: 1645-1646.

  24. Carpenter JR, Bunch TW, Engerl AG et al. Survival in polymyositis: Corticosteroids and risk factors. J Rheumatol 1977; 4: 207-214.

  25. Henrikkson KG, Sandstedt P. Polymyositis-treatment and prognosis: A study of 107 patients. Acta Neurol Scand 1982; 65: 280-300.

  26. Hochbert MC, Feldman D, Stevens MB. Adult onset polymyositis/dermatomyositis: An analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin Arthritis Rheum 1990; 20: 114-120.

  27. Sigurgeirsson B, Lindelof B, Edhag O et al. Risk of cancer in patients with DM or OM: A population based study. N Engl J Med 1992; 326: 363-367.

  28. Cronin ME, Plotz PH. Idiopathic inflammatory myopathies. Rheum Dis Clin North Am 1990; 16: 655-665.

  29. Koh ET, Seow A, Ong B et al. Adult onset polymyositis/dermatomyositis: Clinical and laboratory features and treatment response in 75 patients. Ann Rheum Dis 1993; 52: 857-861.

  30. Tymms KE, Webb J. Dermatopolymyositis and other connective tissue diseases: A review of 105 cases. J Rheumatol 1985; 12: 1140-1148.

  31. Holden DJ, Brownell AKW, Fritzler MJ. Clinical and serologic features of patients with polymyositis or dermatomyositis. Can Med Assoc J 1985; 132: 649-653.

  32. Lundbert I, Nennesmo I, Hedfords E. A clinical, serological and histopathological study of myositis patients with and without anti-RNP antibodies. Semin Arthritis Rheum 1992; 22: 127-138.

  33. Benbassat J, Gefel D, Larholt K et al. Prognostic factors in polymyositis/dermatomyositis: A computer-assisted analysis of ninety-two cases. Arthritis Rheum 1985; 28: 249-255.

  34. Ramirez G, Asherson RA, Kharnashta MA et al. Adult-onset polymyositis/dermatomyositis: Description of 25 patients with emphasis on treatment. Semin Arthritis Rheum 1990; 20: 114-120.

  35. Sabroe RA, Wallington TB, Kennedy CT. Dermatomyositis treated with high-dose intravenous immunoglobulins and associated with panniculitis. Clin Exp Derm 1995; 20: 164-167.

  36. Bohan A, Peter JB, Bowman RL et al. A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977; 56: 255-286.

  37. Dalakas MC. Clinical, immunopathologic and therapeutic considerations of inflammatory myopathies. Clin Neuropharmacol 1992; 15: 327-351.

  38. Miller FW. Classification and prognosis of inflammatory muscle disease. Rheum Dis Clin North Am 1994; 20: 811-826.




2020     |     www.medigraphic.com